
ABSTRACT Objective Describe genetic diagnoses and characterize postnatal outcomes in a prenatal cohort of arthrogryposis multiplex congenita (AMC) evaluated at a quaternary fetal center. Methods Retrospective cohort study of pregnancies referred between 2014 and 2026 for contractures involving ≥ 2 body areas. We categorized cases into three groups using the Hall classification. Demographics, prenatal imaging, genetic results, autopsy findings, and postnatal outcomes were collected. Results Ninety‐four pregnancies were included: 15 with isolated arthrogryposis, 32 with arthrogryposis and systemic anomalies excluding the central nervous system (CNS), and 47 with arthrogryposis and CNS involvement or fetal akinesia deformation sequence (FADS). Genetic findings in our cohort included 18 aneuploidies, 3 copy number variants and 25 single gene disorders. Of pregnancies with non‐diagnostic cytogenetic findings that underwent next‐generation sequencing (NGS), 50% (24/48) had a molecular diagnosis. Neonates with FADS had notably poor outcomes, including high mortality (86%, 6/7) and failed intubation (50%, 3/6) rates. Of neonates with isolated arthrogryposis, 77% (10/13) survived but frequently required respiratory or feeding support, orthopedic surgery, ambulation assistance and had neurodevelopmental delays. Conclusions AMC is genetically heterogeneous with frequent underlying single gene disorders, supporting the use of NGS in prenatal diagnosis. Neonatal morbidity and mortality remain high, particularly with FADS.
ABSTRACT Objective To characterize the quality, consistency, and framing of information about prenatal cell‐free DNA (cfDNA) screening generated by publicly available chatbots, including variation across simulated user age profiles. Methods We conducted a qualitative content analysis of outputs from three publicly available chatbots. To reduce carryover effects and personalization, prompts were entered using a VPN, private browsing, and cleared browser cookies. Outputs were generated using distinct simulated user age profiles. Analysis examined informational completeness, framing of benefits and limitations, terminology, source transparency, and age‐related differences in responses. Results Chatbot outputs varied substantially across platforms and user profiles, with misinformation, omissions, and incomplete information identified. Common themes included inconsistent explanations of the purpose and scope of cfDNA screening, frequent omission of test limitations and downstream implications, and variable readability scores (at a 9th–14th grade level) and terminology that sometimes conflate screening with diagnostic testing. Citations to high‐quality sources were limited or absent. Age‐based profile variation was associated with differences in tone, complexity, and emphasis, suggesting implicit tailoring of information presentation. Conclusion Publicly available chatbots may provide inaccurate or inconsistent information about cfDNA screening. As these tools are increasingly used outside clinical settings, improving accuracy, transparency, discussion of limitations, and source citation is essential to support reliable patient‐facing health information.
ABSTRACT Objective This study explored healthcare professionals’ preferences regarding prenatal genomic testing following the detection of a foetal anomaly and their attitudes towards uncertain results. Method HCPs involved in genetic prenatal diagnostics were asked to fill in a cross‐sectional survey‐based study using a discrete choice experiment to assess their preferences for prenatal genomic testing and attitudes towards uncertain results. Results When ranking the different attributes, diagnostic yield was seen as the most important factor, followed by test safety, waiting time, and the professional responsible for communicating results. Regarding the DCE, respondents favoured tests with a higher probability of obtaining results and shorter turnaround times. The findings also revealed a consistent pattern of caution towards uncertainty, particularly among clinical geneticists compared to gynaecologists who preferred rapid return of test results. Clinical geneticists also assigned greater and almost equal importance to who was communicating the results, time to result, and the reporting of uncertain findings. In addition, respondents chose neither test option in approximately one third of choice tasks, suggesting that healthcare professionals were willing to forgo testing altogether when they perceived the balance between benefits and potential harms was unfavourable. Conclusion The cautious approach observed among healthcare professionals contrasts with findings from studies of prospective parents. Women generally preferred receiving as much information as possible from prenatal testing, including uncertain findings and secondary findings.
ABSTRACT Objective To assess the diagnostic and clinical utility of prenatal exome sequencing (ES) in a cohort of pregnancies using the Clinician‐reported Genetic testing Utility InDEx for Prenatal Care (C‐GUIDE Prenatal). Methods Cases that met criteria for prenatal ES in Ontario, Canada were identified in 5 clinics. Clinicians assessed the utility of ES using C‐GUIDE Prenatal, a clinician‐reported measure of how genetic testing informs pregnancy and neonatal management. Case characteristics were summarized descriptively. C‐GUIDE Prenatal total scores were calculated and regressed against clinically important variables using generalised estimating equations. Results Among 115 cases, the diagnostic yield was 41.7%. The mean C‐GUIDE Prenatal score was 9.48 (SD 11.51). Compared with negative results, informative positive results were associated with an increase in C‐GUIDE Prenatal score of 17.6 ( p < 0.001). Compared to meeting one criterion for ES, meeting ≥ 3 criteria was associated with an increase in C‐GUIDE Prenatal score of 3.8 ( p < 0.05). Compared with pregnancies that were not ongoing at result disclosure, ongoing pregnancy was associated with an increase in the C‐GUIDE Prenatal score of 2.8 ( p < 0.001). Conclusion Findings address a knowledge gap in the clinical value evidence base that informs policy and funding decision‐making for prenatal genetic testing.